東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure = mechanisms and clinical applications : a machine-generated literature overview /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure/ edited by Mukesh Nandave.
Reminder of title:	mechanisms and clinical applications : a machine-generated literature overview /
other author:	Nandave, Mukesh.
Published:	Singapore :Springer Nature Singapore : : 2024.,
Description:	xiv, 528 p. :ill. (chiefly color), digital ;24 cm.
[NT 15003449]:	Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor's effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.
Contained By:	Springer Nature eBook
Subject:	Heart failure - Abstracts. - Pathophysiology -
Online resource:	https://doi.org/10.1007/978-981-97-7568-2
ISBN:	9789819775682

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure = mechanisms and clinical applications : a machine-generated literature overview /
Sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failuremechanisms and clinical applications : a machine-generated literature overview /[electronic resource] :edited by Mukesh Nandave. - Singapore :Springer Nature Singapore :2024. - xiv, 528 p. :ill. (chiefly color), digital ;24 cm.

Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor's effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.

The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.

ISBN: 9789819775682

Standard No.: 10.1007/978-981-97-7568-2doiSubjects--Topical Terms:

3735100
Heart failure
--Pathophysiology--Abstracts.

LC Class. No.: RC685.C53

Dewey Class. No.: 616.129

Sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure = mechanisms and clinical applications : a machine-generated literature overview /
LDR:03125nmm a2200325 a 4500 001 2381146
003 DE-He213
005 20241115120007.0
006 m d
007 cr nn 008maaau
008 250418s2024 si s 0 eng d
020 $a 9789819775682 $q (electronic bk.)
020 $a 9789819775675 $q (paper)
024 7 $a 10.1007/978-981-97-7568-2 $2 doi
035 $a 978-981-97-7568-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC685.C53
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 616.129 $2 23
090 $a RC685.C53 $b S679 2024
245 0 0 $a Sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure $h [electronic resource] : $b mechanisms and clinical applications : a machine-generated literature overview / $c edited by Mukesh Nandave.
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2024.
300 $a xiv, 528 p. : $b ill. (chiefly color), digital ; $c 24 cm.
505 0 $a Chapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor's effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.
520 $a The auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.
650 0 $a Heart failure $x Pathophysiology $v Abstracts. $3 3735100
650 0 $a Enzyme inhibitors $v Abstracts. $3 3735101
650 1 4 $a Pharmacology. $3 634543
650 2 4 $a Biomedical Research. $3 851895
650 2 4 $a Drug Safety and Pharmacovigilance. $3 2108855
650 2 4 $a Clinical Medicine. $3 828964
650 2 4 $a Cardiology. $3 861477
700 1 $a Nandave, Mukesh. $3 3716232
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-97-7568-2
950 $a Medicine (SpringerNature-11650)